

 #IASLCUPDATES

Iniciativa científica de:

A stylized illustration of a pair of lungs in a light blue color, positioned to the left of the main title.

LUNG CANCER UPDATES

IASLC HIGHLIGHTS

7-10 DE SEPTIEMBRE 2019



Con la colaboración de:





Iniciativa científica de:



BARCELONA

Cáncer de pulmón de célula pequeña Mesotelioma/Timoma

Ramón Palmero Sánchez

Hospital Duran i Reynals – Institut Catalá d'Oncologia

L'Hospitalet (Barcelona)

Con la colaboración de:



Cáncer pulmón célula pequeña

OA03 – Systemic Therapies for SCLC: Novel Targets and Patients' Selection

P1.12 – Small cell Lung Cancer / NET (24 posters)

Mesotelioma pleural

MA05 – Update on clinical trials and treatment in pleural mesothelioma.

P1.06 – Mesotelioma (22 posters)

Timoma

P1.15 – Timoma (5 posters)

OA03 - Systemic Therapies for SCLC: Novel Targets and Patients' Selection

OA03.01 - A Non-Randomized, Open-Label, Prospective, Multicenter Study of **Apatinib** as Second-Line and Later-Line Therapy in Patients with ES-SCLC (Q. Liu)

OA03.02 - Effect of **Anlotinib** in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial (Q. Wang)

OA03.03 - Initial Efficacy and Safety Results of **Irinotecan Liposome** Injection (nal-IRI) in Patients with Small Cell Lung Cancer (L. Paz-Ares)

OA03.05 - Characterization of Genomic Alterations in Chinese LCNEC and SCLC via Comprehensive Genomic Profiling (L.Wu)

OA03.06 - ASCL1, NEUROD1, and POU2F3 Drive Distinct Subtypes of Small Cell Lung Cancer with Unique Therapeutic Vulnerabilities (CM. Gay)

OA03.07 - Immune-Related Adverse Events and Clinical Outcome to Anti PD-1 Axis Inhibition in SCLC: A Multicenter Retrospective Analysis (B. Ricciuti)

P1.12 – Small cell Lung Cancer / NET (24 posters)

OA03.01 - A Non-Randomized, Open-Label, Prospective, Multicenter Study of **Apatinib** as Second-Line and Later-Line Therapy in Patients with ES-SCLC (Q. Liu)

Análisis de eficacia de 36 de los 52 pts incluidos.

Población de “buen pronóstico”:

- 83% RT previa
- 47% platino – sensible

Resultados:

- ORR: 19.3%
- DCR: 84%
- mPFS: 6.18m
- mOS: NR
- Tox G3: HTA 8%, proteinuria 2.7%, sd mano-pie 5.5%

OA03.02 - Effect of **Anlotinib** in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial (Q. Wang)

Análisis de los 68 pts que recibieron QTRT previa de los 120 pts incluidos.

46 pacientes Anlotinib (A) vs 22 pacientes Placebo (P)

Pacientes mal balanceados a favor de anlotinib:

- Enfermedad limitada previa: 20% vs 5% (A/P)
- Enfermedad platino – sensible: 24% vs 9% (A/P)

Resultados:

- ORR: 4%
- DCR: 74%
- mPFS: 5.49m
- mOS: 9.49
- Tox G3: HTA 15%, sd mano-pie 6%

Conclusiones: eficacia modesta de los antiangiogénicos en 2L.

OA03.03 – RESILIENT: Initial Efficacy and Safety Results of **Irinotecan Liposome** Injection (nal-IRI) in Patients with Small Cell Lung Cancer (L. Paz-Ares)

85mg/m²: 5 pacientes + 70mg/m²: 25 pacientes

Toxicidad hematológica inferior a topotecán o irinotecán

Grade 3/4 adverse events (%)							
Drug	N	Anemia	Neutropenia	Thrombocytopenia	Vomiting/ Nausea	Fatigue	Diarrhea
Topotecan - IV	107	43.4	88.5	57.6	5.6	4.7	0.9
Topotecano - oral	71	25	61	38	-	4	6
CAV	104	19.8	86.9	14.9	8.7	8.7	0
Irinotecan	16	20	33 (leukopenia)	0	13	-	7
nal-IRI (70mg/m ²)	25	8	26	8	-	4	20

OA03.03 - Initial Efficacy and Safety Results of **Irinotecan Liposome** Injection (nal-IRI) in Patients with Small Cell Lung Cancer (L. Paz-Ares)

85mg/m²: 5 pacientes + 70mg/m²: 25 pacientes

ORR 44%, pero datos aun inmaduros

Drug	Study/Phase	N	ORR (%)	DOR (m)	PSF (m)	OS (m)
Lurbinectedin	NCT02454972 - Phase II	105	35.2	NR (2.1 - 18)	2.0	8.7
Lurbinectedin + Doxorubicin	Phase Ib	27	37	?	3.4	7.9
Temozolamide + Veliparib	NCT01638546 -Phase II	55	39	4.61	3.8	8.2
nal-IRI (70mg/m ²)	RESILIENT - Phase II	25	44	?	?	?

Fase 3 nal-Iri vs topotecán en 2L ongoing.

MA05 – Update on clinical trials and treatment in pleural mesothelioma.

MA05.01 - Second or Third Line Anti-PD-1 Therapy After Multimodality Therapy Including Total Pleurectomy in Malignant Pleural Mesothelioma

MA05.02 - Log Odds of Positive Lymph Nodes Predicts Overall Survival and the Benefit of Postoperative Radiotherapy in Malignant Pleural Mesothelioma (Y. Wo)

MA05.03 - Impact of Time to Surgery on Outcomes in Patients Undergoing Outright Resection for Malignant Pleural Mesothelioma (S. Voigt)

MA05.05 - Post-Discontinuation Treatments in IFCT-GFPC-0701 MAPS Trial: **Real-World Effectiveness of 2nd-Line (2L)** Treatments for Mesothelioma (G. Zalcman)

MA05.06 - Feasibility and Safety of Transarterial Chemoperfusion for Advanced Pleural Mesothelioma: Interim Results of a Phase 2 Study (B. Creelan)

MA05.07 - Efficacy and Safety of Re-Treatment with Tremelimumab and Durvalumab Within the NIBIT-MESO-1 Study (L. Calabro)

MA05.09 - Real-World Data of **Nivolumab** and **Pembrolizumab** in Chemotherapy Pre-Treated Mesothelioma Patients (D. Dumoulin)

MA05.10 - **Pembrolizumab** in the Treatment of Patients with Malignant Pleural Mesothelioma Following Progression After Initial Chemotherapy (K. Cengel)

MA05.11 - Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma (A. Varga)

MA05.05 - Post-Discontinuation Treatments in IFCT-GFPC-0701 MAPS Trial: **Real-World Effectiveness of 2nd-Line (2L) Treatments** for Mesothelioma (G. Zalcman)

342/442 (77.4%) pts recibieron 2ª línea

324 QT: 160 plat doublet, 163 single QT

	2L chemo doublet (Zalcman)	2L single agent chemo (Zalcman)	pem/Pt or pem re- challenge ¹	2L vin ²	2L or 3L nivolumab ₃	pembro in pretreated patients ⁴
Response rate	12.2%	2.6%	19%	16%	19%	20%
Median OS (months from 2L)	13.3	7.7	10.5	9.6	11.9	18.0

Retratamiento con dobletes con platino y la monoQT tienen actividad en 2ª línea, aunque seguimos sin comparaciones aleatorizadas en este setting.

Real-world data de IO en MPM

MA05.09 – Erasmus MC (Rotterdam): 59 pts

MA05.10 – Pennsylvania: 82 pts

	IO trials previos	MA05.09 Erasmus MC	MA05.10 Penn
RP	20 - 29%	12%	25%
mPFS	2.6 – 6.2	2.8	4.2
mOS	11.8 – 18m	6.4	8.5

Los resultados en RWD de IO son discretamente inferiores a los reportados en los trials previos.

Esperamos los resultados de los ensayos randomizados de IO en 2L.

All Days

Saturday
September 7

Sunday
September 8

Monday
September 9

Tuesday
September 10

Filter Results:

Tracks ▼

Plenary Sessi..▼

Session No.

Presentation No.

Author / Keyword

Filter

Reset

☐ Show Only CME Accredited Sessions



PL02 - Presidential Symposium including Top 7 Rated Abstracts

08:00 - 10:15 | 9/09/2019 | Location: Barcelona (2005)

Type: Plenary Session | Track:

Moderators: Giorgio Vittorio Scagliotti, Ramon Rami-Porta

CME Accredited



PL02.11 - Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

09:38 - 09:48 | Presenting Author(s): Luis Paz-Ares | Author(s): Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, György Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Norah Shire, Haiyi Jiang, Jonathan Goldman

Iniciativa científica de: